The ISSCR Joins Coalition Letter Urging Reauthorization of the U.S. Rare Pediatric Disease Priority Review Voucher Program

The ISSCR joined more than 170 organizations representing scientists, physicians, and patient advocates in urging the U.S. Congress to reauthorize the Rare Pediatric Disease Priority Review Voucher (PRV) program. The PRV program provides a proven incentive for developing cell and gene therapies for children with rare diseases by driving private investment without additional taxpayer costs. The program has been successful in advancing research that addresses unmet clinical needs while strengthening the broader research and development ecosystem for cell and gene therapies.

 Read the letter.